ABSI — Absci Corporation

Is ABSI overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Absci Corporation (ABSI) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $7.47. The rating moved from Strong Oversold to Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Absci Corporation (ABSI) is a platform-focused biotech with an AI-enabled discovery approach that can attract partner interest and produce discrete data-driven catalysts. Financially the company is typical of small-cap discovery firms — meaningful cash burn and sensitivity to financing markets create dilution risk and short-term volatility. Upside scenarios include positive program readouts or licensing/partnership announcements that validate the platform and extend runway; downside scenarios center on weak data, funding limitations, or a sector rotation away from small-cap biotech that would pressure valuation and liquidity. Given limited public/social coverage and near-term financing risk, expect episodic price moves tied to news and capital markets conditions.

Key factors

  • Platform-driven discovery combining biologics/AI capabilities that can attract partnerships or licensing opportunities
  • Early-stage pipeline that creates discrete binary catalysts (data readouts, collaborations) which can drive episodic upside
  • Capital structure and cash runway sensitivity in a market where convertible/debt financings are pressuring mid/small-cap biotech dilution
  • Sector flows favoring growth but with rotation into large-cap pharma potentially limiting small-cap funding and defensive allocations
  • Limited public/social research coverage and potentially low liquidity, increasing volatility around news events
  • Readthroughs from recent sector approvals and commercial shifts that could benefit service and distribution partners, indirectly supporting platform commercialization options

Risks

  • High cash burn and likelihood of future equity or convertible financings leading to dilution
  • Program-level failure or negative data from discovery/early development efforts
  • Competition from larger pharma and AI-driven discovery startups with greater scale and resources
  • Low trading liquidity and investor attention increasing price sensitivity to headlines
  • Regulatory and commercialization uncertainty for platform-derived assets and any partnered programs
  • Broader market/sector sentiment turning defensive, reducing access to capital and slowing partnership activity

See today's live rating, score and targets

Members see the live hourly rating for ABSI — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.